1 |
Chow LQM. Head and neck cancer[J]. N Engl J Med, 2020, 382(1): 60-72.
|
2 |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA A Cancer J Clin, 2020, 70(1): 7-30.
|
3 |
Cohen EEW, Soulières D, Le Tourneau C, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study[J]. The Lancet, 2019, 393(10167): 156-167.
|
4 |
Barnoud T, Schmidt ML, Donninger H, et al. The role of the NORE1A tumor suppressor in oncogene-induced senescence[J]. Cancer Lett, 2017, 400: 30-36.
|
5 |
Donninger H, Schmidt ML, Mezzanotte J, et al. Ras signaling through RASSF proteins[J]. Semin Cell Dev Biol, 2016, 58: 86-95.
|
6 |
Zhou XH, Yang CQ, Zhang CL, et al. RASSF5 inhibits growth and invasion and induces apoptosis in osteosarcoma cells through activation of MST1/LATS1 signaling[J]. Oncol Rep, 2014, 32(4): 1505-1512.
|
7 |
Liu LL, Zhang MF, Pan YH, et al. NORE1A sensitises cancer cells to sorafenib-induced apoptosis and indicates hepatocellular carcinoma prognosis[J]. Tumor Biol, 2014, 35(3): 1763-1774.
|
8 |
Steinmann K, Sandner A, Schagdarsurengin U, et al. Frequent promoter hypermethylation of tumor-related genes in head and neck squamous cell carcinoma[J]. Oncol Rep, 2009, 22(6): 1519-1526.
|
9 |
Han L, Dong Z, Wang C, et al. Decreased expression and aberrant methylation of RASSF5A correlates with malignant progression of gastric cardia adenocarcinoma[J]. Mol Carcinog, 2015, 54(12): 1722-1733.
|
10 |
Liu G, Liu B, Zheng S, et al. Aberrant RASSF5 gene transcribed region hypermethylation in pediatric hepatoblastomas[J]. Int J Clin Exp Pathol, 2018, 11(7): 3612-3617.
|
11 |
Guo W, Wang C, Guo YL, et al. RASSF5A, a candidate tumor suppressor, is epigenetically inactivated in esophageal squamous cell carcinoma[J]. Clin Exp Metastasis, 2015, 32(1): 83-98.
|
12 |
Zhou BP, Deng J, Xia WY, et al. Dual regulation of Snail by GSK-3β-mediated phosphorylation in control of epithelial-mesenchymal transition[J]. Nat Cell Biol, 2004, 6(10): 931-940.
|
13 |
Sun J, Meng D, Yu T, et al. N-terminal truncated carboxypeptidase E represses E-cadherin expression in lung cancer by stabilizing the Snail-HDAC complex[J]. Am J Cancer Res, 2020, 10(3): 925-938.
|
14 |
An P, Chen F, Li Z, et al. HDAC8 promotes the dissemination of breast cancer cells via AKT/GSK-3β/Snail signals[J]. Oncogene, 2020, 39(26): 4956-4969.
|
15 |
Domoto T, Pyko IV, Furuta T, et al. Glycogen synthase kinase-3β is a pivotal mediator of cancer invasion and resistance to therapy[J]. Cancer Sci, 2016, 107(10): 1363-1372.
|
16 |
Jin F, Wu Z, Hu X, et al. The PI3K/Akt/GSK-3β/ROS/eIF2B pathway promotes breast cancer growth and metastasis via suppression of NK cell cytotoxicity and tumor cell susceptibility[J]. Cancer Biol Med, 2019, 16(1): 38-54.
|
17 |
Liao TJ, Tsai CJ, Jang H, et al. RASSF5: an MST activator and tumor suppressor in vivo but opposite in vitro[J]. Curr Opin Struct Biol, 2016, 41: 217-224.
|
18 |
Donninger H, Calvisi DF, Barnoud T, et al. NORE1A is a Ras senescence effector that controls the apoptotic/senescent balance of p53 via HIPK2[J]. J Cell Biol, 2015, 208(6): 777-789.
|
19 |
Li BT, Yu C, Xu Y, et al. TET1 inhibits cell proliferation by inducing RASSF5 expression[J]. Oncotarget, 2017, 8(49): 86395-86409.
|
20 |
Sun HY, Yang D, Mi J, et al. Histone demethylase Jmjd3 modulates osteoblast apoptosis induced by tumor necrosis factor-α through directly targeting RASSF5[J]. Connect Tissue Res, 2020, 61(6): 517-525.
|